KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Halozyme Therapeutics (HALO) EPS (Weighted Average and Diluted) (2016 - 2025)

Halozyme Therapeutics (HALO) has disclosed EPS (Weighted Average and Diluted) for 14 consecutive years, with -$1.13 as the latest value for Q4 2025.

  • On a quarterly basis, EPS (Weighted Average and Diluted) fell 206.6% to -$1.13 in Q4 2025 year-over-year; TTM through Dec 2025 was $2.56, a 25.36% decrease, with the full-year FY2025 number at $2.56, down 25.36% from a year prior.
  • EPS (Weighted Average and Diluted) was -$1.13 for Q4 2025 at Halozyme Therapeutics, down from $1.43 in the prior quarter.
  • In the past five years, EPS (Weighted Average and Diluted) ranged from a high of $1.48 in Q3 2021 to a low of -$1.13 in Q4 2025.
  • A 5-year average of $0.61 and a median of $0.6 in 2023 define the central range for EPS (Weighted Average and Diluted).
  • Peak YoY movement for EPS (Weighted Average and Diluted): soared 575.0% in 2021, then plummeted 206.6% in 2025.
  • Halozyme Therapeutics' EPS (Weighted Average and Diluted) stood at $0.46 in 2021, then decreased by 10.87% to $0.41 in 2022, then soared by 58.54% to $0.65 in 2023, then soared by 63.08% to $1.06 in 2024, then plummeted by 206.6% to -$1.13 in 2025.
  • Per Business Quant, the three most recent readings for HALO's EPS (Weighted Average and Diluted) are -$1.13 (Q4 2025), $1.43 (Q3 2025), and $1.33 (Q2 2025).